MC
LIMNW

Meteora Capital’s Liminatus Pharma Warrants LIMNW Stock Holding History

Meteora Capital’s Portfolio LIMNW Stock Details LIMNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,000
Closed -$2.22K – 452
2025
Q3 		$2.22K Hold
15,000
– – ﹤0.01% 282
2025
Q2 		$3.6K Buy
+15,000
New +$2.95K ﹤0.01% 166

Other funds holding LIMNW

CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.4% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Meteora Capital's LIMNW Position: Q4 2025 in Review

Meteora Capital sold out of Liminatus Pharma Warrants (LIMNW) in Q4 2025, closing a stake of 15,000 shares — an estimated $2.22K sold.

Meteora Capital first reported a position in LIMNW in Q2 2025 and held it in 2 quarters. The position peaked at $3.6K in Q2 2025. 24 funds tracked by Wall St. Rank hold LIMNW as of Q4 2025.

  • Meteora Capital reported no remaining Liminatus Pharma Warrants position as of Q4 2025 after selling out during the quarter.
  • Meteora Capital sold 15,000 Liminatus Pharma Warrants shares in Q4 2025, an estimated $2.22K.
  • Meteora Capital first reported a position in Liminatus Pharma Warrants in Q2 2025 and held it in 2 quarters.
  • Meteora Capital's Liminatus Pharma Warrants position peaked at $3.6K in Q2 2025.
  • 24 funds tracked by Wall St. Rank held Liminatus Pharma Warrants as of Q4 2025.

Based on Meteora Capital's 13F filing for Q4 2025, filed 17 Feb 2026.